# US 2020/0392114 A1 · SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZINE-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392114 A1
- Document ID: US20200392114A1
- Status: Published application
- Kind: A1
- Application number: 17/006,317
- Filed: 2020-08-28
- Published: 2020-12-17
- Earliest claimed: 2018-10-29
- Assignees: FORMA Therapeutics, Inc.
- Applicants: FORMA Therapeutics, Inc.
- Inventors: George P. LUKE; Stephen HUBBS; Matthew W. MARTIN; Shawn E.R. SCHILLER; Robert WENSLOW; Yawei SHI; Jun HUANG
- Web page: https://patentgrep.com/patent/US20200392114A1

## CPC

- C07D 403/10: linked by a carbon chain containing aromatic rings
- A61P 35/00: Antineoplastic agents
- C07D 295/104: with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone:

## Claims

### Claim 1

A solid form of Compound 1 free base:
wherein the solid form is selected from the group consisting of Mixture A, Form B, Form C, Form X, and Form Z.

### Claim 2 (depends on 1)

The solid form of claim 1, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.

### Claim 3 (depends on 1)

The solid form of claim 1, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 15.4, 19.6, and 22.3 and not having a diffraction at angle (2 theta±0.2) of 24.2.

### Claim 4 (depends on 1)

The solid form of claim 1, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 12.6, 13.9, 15.4, 16.4, 19.6, 20.2, 22.3, 23.4, 23.8, and 25.3.

### Claim 5 (depends on 3)

The solid form of claim 3, wherein the solid form is Form B and is characterized by a DSC endotherm having an endotherm at about 226° C.

### Claim 6 (depends on 3)

The solid form of claim 3, wherein the solid form is Form B and is characterized by a TGA with a weight loss of about 0.5% between 21° C. and 100° C.

### Claim 7 (depends on 3)

The solid form of claim 3, wherein the solid form is Form B and is characterized by a DVS of about 0.5% water by weight below 95% relative humidity.

### Claim 8 (depends on 1)

The solid form of claim 1, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, and 26.6.

### Claim 9 (depends on 1)

The solid form of claim 1, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 15.4, 19.6, 22.3, 24.2, and 26.6.

### Claim 10 (depends on 1)

The solid form of claim 1, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 7.2, 8.5, 14.9, 16.1, and 17.8.

### Claim 11

A composition comprising Compound 1 free base Mixture A:
wherein Mixture A is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.

### Claim 12 (depends on 11)

The composition of claim 11, wherein Mixture A is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, 21.0, and 22.3.

### Claim 13

A pharmaceutical composition comprising a solid form of Compound 1 free base:
and a pharmaceutically acceptable carrier, wherein the solid form of Compound 1 is Form B and is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 15.4, 19.6, and 22.3 and not having a diffraction at angle (2 theta±0.2) of 24.2.

### Claim 15 (depends on 13)

The pharmaceutical composition of claim 13, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 15.4, 19.6, and 22.3 and not having a diffraction at angle (2 theta±0.2) of 24.2.

### Claim 16 (depends on 13)

The pharmaceutical composition of claim 13, wherein the solid form is characterized by an XRPD pattern having diffractions at angles (2 theta±0.2) of 9.6, 10.1, 12.6, 13.9, 15.4, 16.4, 19.6, 20.2, 22.3, 23.4, 23.8, and 25.3.

### Claim 17 (depends on 13)

The pharmaceutical composition of any one of claim 13, wherein the pharmaceutical composition is substantially free of Solid Form X.

### Claim 18 (depends on 13)

The pharmaceutical composition of any one of claim 13, wherein the pharmaceutical composition is substantially free of Solid Forms C, X, and Z.

### Claim 19

A solid form of Compound 1:
wherein the solid form is the form that would be obtained by a process comprising:
suspending at least one of Mixture A, Form C, and Form X of Compound 1 in a solvent selected from a group consisting of ethyl acetate (EtOAc), acetonitrile (ACN), heptane, isopropyl alcohol (IPA), and ethanol (EtOH) to provide a slurry; and
maintaining the slurry for a period of at least 5 hours to afford the solid form of Compound 1.

### Claim 20 (depends on 19)

The solid form of claim 19, wherein the slurry is heated to a temperature from about 50° C. to about 100° C. after suspension in the solvent.

### Claim 21 (depends on 19)

The solid form of claim 19, further comprising isolating the solid form of Compound 1 from the slurry.
